Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?

International Journal of General Medicine

Volumn 10, Issue , 2017, Pages 23-26

  Ampudia Blasco, Francisco Javier ^a   Romera, Irene ^b   Ariño, Bernat ^c   Gomis, Ramón ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b ELI LILLY AND COMPANY   (Spain)

^c Health Economics and Outcomes Research   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

Canagliflozin; Cardiovascular; Dapagliflozin; Empagliflozin; Outcome studies; SGLT2 inhibitors

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN;

ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; GLUCOSURIA; HEART FAILURE; HUMAN; KIDNEY TUBULE ABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RISK REDUCTION; TREATMENT OUTCOME;

EID: 85011114812     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S115566     Document Type: Article

References (16)

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
2. Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2014;10(5):647–663.
3. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12(2):90–100.
4. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012;14(1):83–90.
5. EMA. Jardiance EPAR: Public Assessment Report. 2016. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf. Accessed March 17, 2016.
6. EMA. Ficha técnica Forxiga. 2016. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/ human/002322/WC500136026.pdf. Accessed March 17, 2016.
7. EMA. Ficha técnica Invokana. 2016. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002649/WC500156456.pdf. Accessed March 17, 2016.
8. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217–223 e211.
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471.
10. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–1289.
11. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
12. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
13. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
14. AstraZeneca; Bristol-Myers Squibb; The TIMI Study Group; Hadassah Medical Organization. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARETIMI58). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited 2016 Mar 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534?term=declare+timi+ 58&rank=1. NLM identifier: NCT01730534. Accessed November 7, 2016.
15. Janssen Research & Development; The George Institute for Global Health (Australia). CANVAS – CANagliflozin cardioVascular Assessment Study (CANVAS). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000. [cited 2016 Mar 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT01032629?term=canvas&rank=1. NLM identifier: NCT01032629. Accessed November 7, 2016.
16. Janssen Research & Development; The George Institute for Global Health (Australia). A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). 2000 [cited 2016 17 Mar]. Available from: https://clinicaltrials.gov/ct2/show/NCT01989754?term=canvas&rank=5. NLM identifier: NCT01989754. Accessed November 7, 2016.